CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 100 enrolled
Drug / intervention
CardioFocus HeartLight Endoscopic Ablation Systemdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00971204
NCT00971204Phase 2Completed
CompareCT.gov

Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) for the Treatment of Symptomatic Atrial Fibrillation

CardioFocus·interventional·Posted Sep 3, 2009·Updated Aug 1, 2016

In Brief

A Phase 2 clinical trial evaluating CardioFocus HeartLight Endoscopic Ablation System for Paroxysmal Atrial Fibrillation. Completed, enrolled 100 participants across 10 sites.

Detailed Summary

This is a demonstration of safety and efficacy of the ablation for pulmonary vein isolation in the treatment of paroxysmal atrial fibrillation.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParoxysmal Atrial Fibrillation
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 3, 2009
Enrollment StartSep 1, 2009
Primary CompletionDec 1, 2011
Study CompletionJun 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 16.8 years ago

Interventions

CardioFocus HeartLight Endoscopic Ablation Systemdevice

PVI ablation